论文部分内容阅读
目的观察益气化痰汤辅助治疗老年晚期肺癌的临床疗效及安全性。方法将81例老年晚期肺癌患者随机分为对照组40例与试验组41例。对照组予以第1天静脉滴注75 g·m~(-2)紫杉醇注射液+第1天静脉滴注60 mg·m~(-2)顺铂+口服吉非替尼250 mg,qd;试验组在对照组治疗的基础上,予以口服益气化痰汤,每天1剂。2组患者一个周期均为7 d,共治疗4个周期。比较2组患者的临床疗效、血清癌胚抗原(CEA)、细胞角蛋白19片段(CYFRA21-1)、神经特异性烯醇化酶(NSE)、血管内皮生长因子(VEGF)、细胞外信号调节激酶(ERK)水平,以及药物不良反应的发生情况。结果治疗后,试验组和对照组的疾病控制率分别为90.24%(37/41例)和72.50%(29/40例),差异有统计学意义(P<0.05)。治疗后,试验组与对照组的CEA分别为(92.74±10.57),(120.45±13.96)ng·mL~(-1);CYFRA21~(-1)分别为(92.74±10.57),(114.54±11.74)ng·mL~(-1);NSE分别为(7.04±0.81),(8.45±0.94)ng·mL~(-1);ERK分别为(0.97±0.11),(1.49±0.16)μg·mL~(-1);VEGF分别为(5.80±0.63),(17.74±1.92)ng·mL~(-1),差异均有统计学意义(均P<0.05)。试验组的0.5,1,2年生存率分别为97.56%,95.12%,90.24%,对照组的0.5,1,2年生存率分别为92.50%,87.50%,72.50%,差异均有统计学意义(均P<0.05)。2组患者的药物不良反应以胸痛、呕吐合并食欲缺乏、发热为主,试验组和对照组的药物不良反应发生率分别为7.32%和17.50%,差异有统计学意义(P<0.05)。结论益气化痰汤辅助治疗老年晚期肺癌的临床疗效显著,且安全性较高。
Objective To observe the clinical efficacy and safety of Yiqi Huatan Decoction in adjuvant treatment of elderly patients with advanced lung cancer. Methods Eighty-one elderly patients with advanced lung cancer were randomly divided into control group (n = 40) and experimental group (n = 41). The control group was given intravenous drip of 75 g · m ~ (-2) paclitaxel on the first day and intravenous infusion of 60 mg · m ~ (-2) cisplatin + gefitinib 250 mg qd on the first day. The experimental group in the control group based on the treatment, to be oral Yiqi Huatan soup, a day. One cycle of both groups was 7 days, a total of 4 cycles. The clinical efficacy, serum CEA, CYFRA21-1, NSE, VEGF, extracellular signal-regulated kinase (ERK) levels, and the incidence of adverse drug reactions. Results After the treatment, the disease control rates of the experimental group and the control group were 90.24% (37/41 cases) and 72.50% (29/40 cases) respectively, the difference was statistically significant (P <0.05). After treatment, the CEA of the experimental group and the control group were (92.74 ± 10.57) and (120.45 ± 13.96) ng · mL -1, respectively. The CYFRA21 -1 levels were (92.74 ± 10.57) and (114.54 ± 11.74 (0.97 ± 0.11) and (1.49 ± 0.16) μg · mL -1, respectively. The levels of ERK were (7.04 ± 0.81) and (8.45 ± 0.94) ng · mL -1 ~ (-1) and VEGF (5.80 ± 0.63) and (17.74 ± 1.92) ng · mL ~ (-1) respectively, all with statistical significance (all P <0.05). The 0.5, 1, 2-year survival rates of the experimental group were 97.56%, 95.12% and 90.24%, respectively. The 0.5, 1 and 2-year survival rates of the control group were 92.50%, 87.50% and 72.50%, respectively, with significant differences (All P <0.05). Two groups of patients with adverse drug reactions to chest pain, vomiting with loss of appetite, fever, test group and control group, the incidence of adverse drug reactions were 7.32% and 17.50%, the difference was statistically significant (P <0.05). Conclusion Yiqi Huatan decoction adjuvant treatment of elderly patients with advanced lung cancer clinical efficacy was significant and safe.